L-Adrenalin Spritzfertig Fresenius (Epinephrine)

Epinephrine activates α‑ and β‑adrenergic receptors throughout the body. α‑receptor stimulation causes vasoconstriction, raising blood pressure, while β1‑receptor activation increases heart rate and contractility. β2‑receptor activation relaxes bronchial smooth muscle, producing bronchodilation. Together these actions restore airway patency, improve circulation, and support cardiac function during an emergency.

The dose of L‑Adrenalin Spritzfertig is determined by the prescribing clinician based on the patient’s age, weight, severity of the reaction and the route of administration. Healthcare providers follow established emergency‑care protocols and adjust the amount accordingly; no fixed public dosing schedule is provided.

Safety data for epinephrine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

L‑Adrenalin’s active ingredient, epinephrine, provides both α‑ and β‑adrenergic activity, offering simultaneous vasoconstriction, cardiac stimulation and bronchodilation. Alternatives such as norepinephrine lack significant β2 activity and are therefore less effective for bronchospasm, while agents like albuterol target only β2 receptors and do not address circulatory collapse. Epinephrine remains the first‑line choice for combined anaphylactic and cardiac emergencies.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Keep the spray in its original packaging until use, and inspect for any discoloration or particulate matter before administration.

L‑Adrenalin Spritzfertig is supplied as a ready‑to‑use spray solution for injection. Trained personnel deliver the dose intravenously or via endotracheopulmonary (inhalation) routes, following emergency protocols. The device is designed for rapid, accurate dosing without the need for reconstitution.

Serious adverse events include life‑threatening arrhythmias, hypertensive crisis, myocardial ischemia, pulmonary edema, and tissue necrosis at the injection site. These risks are heightened in patients with pre‑existing cardiovascular disease, uncontrolled hypertension, or when excessive doses are administered.

Patients with a known hypersensitivity to epinephrine or any component of the formulation should not receive L‑Adrenalin Spritzfertig. Caution is also advised for individuals with severe coronary artery disease, uncontrolled hypertension, or certain cardiac arrhythmias, where the drug’s potent adrenergic effects may exacerbate the condition.